A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

610 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-27

Study Completion Date

2028-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to learn about risk of progressive pulmonary fibrosis (PPF). The main questions it aims to answer are:

* Risk factors of PPF
* Prevalence of PPF
* Mortality of PPF

Patients with interstitial lung disease (ILD) of known or unknown etiology other than IPF who has radiological evidence of pulmonary fibrosis will enroll in this study.

* All participants will have baseline investigations at the first visit having provided informed consent.
* At the first visit, baseline characteristics will be collected including demographics, medical history, smoking history, complications and medication use. 50 mL of blood will be obtained. High resolution computed tomography (HRCT), full lung function tests and a 6 min walk test will be performed.
* Further visits at 6 months and 12 months will include further 50 mL blood sampling. HRCT, full lung function tests and a 6 min walk test will be repeated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment

NCT05875532

Lung Diseases, Interstitial

COMPLETED

Prospective Study to Observe and Manage Progression of Pulmonary Nodules

NCT05511090

Lung Nodules

UNKNOWN

Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis

NCT02594059

Pulmonary Fibrosis

COMPLETED NA

Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)

NCT00258544

Pulmonary Fibrosis

ACTIVE_NOT_RECRUITING

Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)

NCT00373841

Idiopathic Pulmonary Fibrosis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interstitial Lung Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PF

Patients with interstitial lung disease (ILD) of known or unknown etiology other than IPF who has radiological evidence of pulmonary fibrosis(PF).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-80 years old
* Agree and sign the informed consent form
* Interstitial lung disease patients with imaging features of pulmonary fibrosis

Exclusion Criteria

* Patients with idiopathic pulmonary fibrosis (IPF)
* Pregnant or lactating women
* mental illness or cognitive impairment
* participating in other clinical studies
* Unable to sign informed consent form

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No